

Edgar Filing: ICN PHARMACEUTICALS INC - Form SC 13D/A

ICN PHARMACEUTICALS INC
Form SC 13D/A
April 09, 2002

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

SCHEDULE 13D
(Rule 13d-101)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a)
AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a)

(Amendment #2)

ICN Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, par value \$0.01 per share ("Shares")

(Title of Class of Securities)

44 8924 100

(CUSIP Number)

David L. Cohen
Principal
Iridian Asset Management LLC
276 Post Road West
Westport, CT 06880-4704
203-341-9000

David Winters
President
Franklin Mutual Advisers, LLC
51 John F. Kennedy Parkway
Short Hills, New Jersey 07078
973-912-2177

with a copy to:

Daniel S. Sternberg, Esq.
Cleary, Gottlieb, Steen & Hamilton
One Liberty Plaza
New York, New York 10006
212-225-2000

(Name, Address and Telephone Number of Persons Authorized to Receive
Notices and Communications)

April 9, 2002

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. (As to the Iridian Reporting Persons (as defined below) only.)

The information required on this cover page shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Act"), or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

Edgar Filing: ICN PHARMACEUTICALS INC - Form SC 13D/A

(Continued on the following pages)
(Page 1 of 17 Pages)

CUSIP No. 13D8924 100

- 1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

Iridian Asset Management LLC

- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) |
(b) |
3 SEC USE ONLY

- 4 SOURCE OF FUNDS

WC

- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEM 2(d) or 2(e) |

- 6 CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7	SOLE VOTING POWER 0
	8	SHARED VOTING POWER 4,714,557
	9	SOLE DISPOSITIVE POWER 0
	10	SHARED DISPOSITIVE POWER 4,714,557

- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
4,714,557

- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES |

Disclaims beneficial ownership for all purposes of the Common
Stock held by FMA, FRI or Providence (See Items 4 and 5(a))

- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
5.7% (See Item 5(a))

- 14 TYPE OF REPORTING PERSON

IA

Edgar Filing: ICN PHARMACEUTICALS INC - Form SC 13D/A

CUSIP No. 13D8924 100

1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

LC Capital Management, LLC

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) |
(b) |

3 SEC USE ONLY

4 SOURCE OF FUNDS

WC

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEM 2 (d) or 2 (e) |

6 CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF SHARES
BENEFICIALLY OWNED BY
EACH REPORTING PERSON
WITH

7 SOLE VOTING POWER
0

8 SHARED VOTING POWER
4,714,557

9 SOLE DISPOSITIVE POWER
0

10 SHARED DISPOSITIVE POWER
4,714,557

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

4,714,557

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES |

Disclaims beneficial ownership for all purposes of the Common
Stock held by FMA, FRI or Providence (See Items 4 and 5(a))

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

5.7% (See Item 5(a))

14 TYPE OF REPORTING PERSON

HC

Edgar Filing: ICN PHARMACEUTICALS INC - Form SC 13D/A

CUSIP No. 13D8924 100

- 1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

CL Investors, Inc.

- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) |
3 SEC USE ONLY (b) |

- 4 SOURCE OF FUNDS

WC

- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEM 2 (d) or 2 (e) |

- 6 CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF SHARES
BENEFICIALLY OWNED BY
EACH REPORTING PERSON
WITH

- 7 SOLE VOTING POWER
0

- 8 SHARED VOTING POWER
4,714,557

- 9 SOLE DISPOSITIVE POWER
0

- 10 SHARED DISPOSITIVE POWER
4,714,557

- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

4,714,557

- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES |

Disclaims beneficial ownership for all purposes of the Common
Stock held by FMA, FRI or Providence (See Items 4 and 5(a))

- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

5.7% (See Item 5(a))

- 14 TYPE OF REPORTING PERSON

HC

Edgar Filing: ICN PHARMACEUTICALS INC - Form SC 13D/A

CUSIP No. 13D8924 100

- 1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

COLE Partners LLC
- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) (b)
- 3 SEC USE ONLY
- 4 SOURCE OF FUNDS

WC
- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)
- 6 CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware
- | | |
|--|--|
| NUMBER OF SHARES
BENEFICIALLY OWNED BY
EACH REPORTING PERSON
WITH | 7 SOLE VOTING POWER
0 |
| | 8 SHARED VOTING POWER
108,500 |
| | 9 SOLE DISPOSITIVE POWER
0 |
| | 10 SHARED DISPOSITIVE POWER
108,500 |
- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

108,500
- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

Disclaims beneficial ownership for all purposes of the Common Stock held by FMA, FRI or Providence (See Items 4 and 5(a))
- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

0.1% (See Item 5(a))
- 14 TYPE OF REPORTING PERSON

HC

CUSIP No. 13D8924 100

Edgar Filing: ICN PHARMACEUTICALS INC - Form SC 13D/A

-
- 1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

Iridian Private Business Value Equity Fund, L.P.
- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) |
(b) |
- 3 SEC USE ONLY
- 4 SOURCE OF FUNDS

WC
- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEM 2 (d) or 2 (e) |
- 6 CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware
- | | |
|--|--|
| NUMBER OF SHARES
BENEFICIALLY OWNED BY
EACH REPORTING PERSON
WITH | 7 SOLE VOTING POWER
0 |
| | 8 SHARED VOTING POWER
108,500 |
| | 9 SOLE DISPOSITIVE POWER
0 |
| | 10 SHARED DISPOSITIVE POWER
108,500 |
- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

108,500
- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES |

Disclaims beneficial ownership for all purposes of the Common
Stock held by FMA, FRI or Providence (See Items 4 and 5(a))
- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

0.1% (See Item 5(a))
- 14 TYPE OF REPORTING PERSON

PN

CUSIP No. 13D8924 100

Edgar Filing: ICN PHARMACEUTICALS INC - Form SC 13D/A

1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

David L. Cohen

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) |
(b) |

3 SEC USE ONLY

4 SOURCE OF FUNDS

WC

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEM 2(d) or 2(e) |

6 CITIZENSHIP OR PLACE OF ORGANIZATION

United States

NUMBER OF SHARES
BENEFICIALLY OWNED BY
EACH REPORTING PERSON
WITH

7 SOLE VOTING POWER

0

8 SHARED VOTING POWER

4,807,557

9 SOLE DISPOSITIVE POWER

0

10 SHARED DISPOSITIVE POWER

4,807,557

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

4,807,557

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES |

Disclaims beneficial ownership for all purposes of the Common
Stock held by FMA, FRI or Providence (See Items 4 and 5(a))

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

5.8% (See Item 5(a))

14 TYPE OF REPORTING PERSON

IN

CUSIP No. 13D8924 100

1 NAMES OF REPORTING PERSONS

Edgar Filing: ICN PHARMACEUTICALS INC - Form SC 13D/A

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

Harold J. Levy

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) (b)

3 SEC USE ONLY

4 SOURCE OF FUNDS

WC

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

6 CITIZENSHIP OR PLACE OF ORGANIZATION

United States

NUMBER OF SHARES
BENEFICIALLY OWNED BY
EACH REPORTING PERSON
WITH

7 SOLE VOTING POWER
0

8 SHARED VOTING POWER
4,807,557

9 SOLE DISPOSITIVE POWER
0

10 SHARED DISPOSITIVE POWER
4,807,557

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

4,807,557

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

Disclaims beneficial ownership for all purposes of the Common Stock held by FMA, FRI or Providence (See Items 4 and 5(a))

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

5.8% (See Item 5(a))

14 TYPE OF REPORTING PERSON

IN

CUSIP No. 13D8924 100

1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

Edgar Filing: ICN PHARMACEUTICALS INC - Form SC 13D/A

Franklin Mutual Advisers, LLC

- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) |
3 SEC USE ONLY (b) |

4 SOURCE OF FUNDS

WC

- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2 (d) or 2 (e) |

6 CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF SHARES
BENEFICIALLY OWNED BY
EACH REPORTING PERSON
WITH

7 SOLE VOTING POWER
3,346,973

8 SHARED VOTING POWER
0

9 SOLE DISPOSITIVE POWER
3,346,973

10 SHARED DISPOSITIVE POWER
0

- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,346,973

- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES |

Disclaims beneficial ownership for all purposes of the Common Stock held by FMA, FRI or Providence (See Items 4 and 5(a))

- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
4.0% (See Item 5(a))

- 14 TYPE OF REPORTING PERSON
IA

This Amendment No. 2 (this "Amendment") amends and supplements the Schedule 13D filed on March 13, 2002, of the Reporting Persons, as amended by Amendment No. 1 thereto, filed on March 25, 2002, with respect to the common stock, par value \$0.01 per share (the "Common Stock"), of ICN Pharmaceuticals, Inc., a Delaware corporation (the "Issuer") (such Statement on Schedule 13D as amended, the "Schedule 13D"). All capitalized terms used in this Amendment and not otherwise defined herein have the meanings ascribed to such terms in the Schedule 13D.

Item 3. Source and Amount of Funds or Other Consideration.

Edgar Filing: ICN PHARMACEUTICALS INC - Form SC 13D/A

Item 3 of the Schedule 13D is amended to read in its entirety as follows:

(1) Iridian Reporting Persons.

The securities reported in Item 5 as beneficially owned by the Iridian Reporting Persons were acquired as follows:

Iridian purchased 100 shares of Common Stock for total consideration (including brokerage commissions) of \$3,287.95 derived from the capital of Iridian.

Accounts managed by Iridian (excluding Iridian Private Business) purchased an aggregate of 4,605,957 shares of Common Stock for total consideration (including brokerage commissions) of approximately \$141.1 million derived from the capital of the managed accounts.

Iridian Private Business purchased an aggregate of 108,500 shares of Common Stock for a total consideration (including brokerage commissions) of approximately \$3.3 million derived from the capital of Iridian Private Business.

First Eagle purchased an aggregate of 93,000 shares of Common Stock for total consideration (including brokerage commissions) of approximately \$2.5 million derived from the capital of First Eagle.

(2) FMA Reporting Persons.

The securities reported in Item 5 as beneficially owned by FMA were acquired with funds of approximately \$98 million (including brokerage commissions). All such funds were provided from investment capital of FMA's respective advisory clients.

Item 4. Purpose of Transaction.

Item 4 of the Schedule 13D is hereby amended by adding the following:

On Tuesday, April 9, 2002, Iridian and FMA delivered to members of the Issuer's board of directors the letter filed as Exhibit 3 to this Amendment.

Item 5. Interest in Securities of the Issuer.

Item 5 of the Schedule 13D is amended to read in its entirety as follows:

(a), (b) As of the date of this statement, the Reporting Persons may be deemed to beneficially own in the aggregate 8,154,530 shares of Common Stock, representing 9.9% of the outstanding Common Stock (the percentage of shares of Common Stock owned being based upon 82,677,075 shares of Common Stock outstanding at March 21, 2002 as set forth in the Issuer's Annual Report on Form 10-K for the year ended December 31, 2001). The Iridian Reporting Persons, on the one hand, and FMA, on the other, each expressly disclaims beneficial ownership for all purposes of the Common Stock held by the other.

(1) Iridian Reporting Persons.

The Iridian Reporting Persons may be deemed to have direct beneficial ownership of shares of Common Stock as follows:

Edgar Filing: ICN PHARMACEUTICALS INC - Form SC 13D/A

Name -----	Number of Shares -----	Percentage -----
Iridian (1)	4,606,057	5.6%
First Eagle	93,000	0.1%
Iridian Private Business	108,500	0.1%

(1) The shares of Common Stock set forth above for Iridian do not include the shares of Common Stock held by Iridian Private Business.

Iridian has direct beneficial ownership of the shares of Common Stock in the accounts which it manages. In addition, Iridian is the investment adviser for Iridian Private Business. In such capacity, Iridian has the right to vote and direct the disposition of shares of Common Stock held by such entities and, consequently, has beneficial ownership of such shares.

LC Capital, as the controlling member of Iridian, may be deemed to possess beneficial ownership of the shares of Common Stock beneficially owned by Iridian. CL Investors, as the controlling member of LC Capital, may be deemed to possess beneficial ownership of the shares of Common Stock beneficially owned by LC Capital. Messrs. Cohen and Levy, as controlling stockholders of CL Investors, may be deemed to possess beneficial ownership of shares of Common Stock beneficially owned by CL Investors. Messrs. Cohen and Levy may also be deemed to possess beneficial ownership of the shares of Common Stock beneficially owned by Iridian by virtue of their service as Principals of Iridian, to possess beneficial ownership of the shares of Common Stock beneficially owned by LC Capital by virtue of their service as Principals and managers of LC Capital, and to possess beneficial ownership of the shares of Common Stock beneficially owned by CL Investors by virtue of the fact that they constitute a majority of CL Investors' Board of Directors. Messrs. Cohen and Levy disclaim beneficial ownership of such shares for all other purposes.

COLE, as the sole general partner of Iridian Private Business, may be deemed to own beneficially shares of Common Stock of which Iridian Private Business may be deemed to possess direct beneficial ownership. Iridian, as the sole member of COLE, may be deemed to possess beneficial ownership of the shares of Common Stock that are beneficially owned by COLE.

Iridian has the direct power to vote or direct the vote, and the direct power to dispose or direct the disposition, of 4,606,057 shares of Common Stock. LC Capital, CL Investors and Messrs. Cohen and Levy may be deemed to share with Iridian the power to vote or direct the vote and to dispose or direct the disposition of such shares.

Iridian has the direct power to vote or direct the vote, and the direct power to dispose or direct the disposition, of the 108,500 shares of Common Stock held by Iridian Private Business. COLE (in addition to LC Capital, CL Investors and Messrs. Cohen and Levy) may be deemed to share with Iridian the power to vote or direct the vote and to dispose or direct the disposition of such shares.

Messrs. Cohen and Levy have the power to vote or direct the vote, and the power to dispose or direct the disposition, of the 93,000 shares of Common Stock held by First Eagle pursuant to their employment with A&SB Advisers described in Item 2 of this statement (which description is incorporated hereby by reference). By virtue of their ability to exercise voting and dispositive power over the shares of Common Stock beneficially owned by First Eagle, Messrs. Cohen and Levy, may be deemed to possess beneficial ownership of such shares. Messrs. Cohen and Levy disclaim beneficial ownership of such shares for all other purposes.

Edgar Filing: ICN PHARMACEUTICALS INC - Form SC 13D/A

(2) FMA Reporting Persons.

One or more of FMA's advisory clients is the owner of 3,346,973 shares of Common Stock. Investment advisory contracts with FMA's advisory clients grant to FMA sole voting and investment discretion over the securities owned by its advisory clients. Therefore, FMA may be deemed to be, for purposes of Regulation 13D-G under the Act, the beneficial owner of 3,346,973 shares, representing approximately 4.0% of the outstanding shares of Common Stock.

FMA is an indirect wholly owned subsidiary of Franklin Resources, Inc. ("FRI"). Beneficial ownership by investment advisory subsidiaries and other affiliates of FRI is being reported in conformity with the guidelines articulated by the SEC staff in Release No. 34-39538 (January 12, 1998) relating to organizations, such as FRI, where related entities exercise voting and investment powers over the securities being reported independently from each other. The voting and investment powers held by FMA are exercised independently from FRI, and from all other investment advisor subsidiaries of FRI (FRI, its affiliates and investment advisor subsidiaries other than FMA are collectively referred to herein as "FRI affiliates"). Furthermore, FMA and FRI internal policies and procedures establish informational barriers that prevent the flow between FMA and the FRI affiliates of information that relates to the voting and investment powers over the securities owned by their respective advisory clients. Consequently, FMA and the FRI affiliates each report the securities over which they hold investment and voting power separately from each other. FMA believes, based upon publicly reported information in financial information services, that other affiliates of FRI may be deemed to have beneficial ownership of securities of the Issuer. No filing pursuant to Regulation 13D-G of the Act has been made by such affiliates and FMA has no direct information in this regard.

Charles B. Johnson and Rupert H. Johnson, Jr. (the "Principal Shareholders") each own in excess of 10% of the outstanding Common Stock of FRI and are the principal shareholders of FRI. However, FMA exercises voting and investment powers on behalf of its advisory clients independently of FRI, the Principal Shareholders, and their respective affiliates. Consequently, beneficial ownership of the securities being reported by FMA is not attributed to FRI, the Principal Shareholders, and their respective affiliates other than FMA. FMA disclaims any economic interest or beneficial ownership in any of the securities of the Issuer that may be beneficially owned by FRI or its other affiliates. FRI disclaims any economic interest or beneficial ownership in any of the securities of the Issuer covered by this statement.

Furthermore, FRI, the Principal Shareholders, and their respective affiliates including FMA, are of the view that they are not acting as a "group" for purposes of Section 13(d) under the Act and that they are not otherwise required to attribute to each other the "beneficial ownership" of securities held by any of them or by any persons or entities advised by FRI subsidiaries.

(c) Other than the transactions described in Schedules IIA and IIB of this statement, none of the Reporting Persons, Jeffrey M. Elliott, nor, to the best of their knowledge, any of the persons listed in Schedule I, have effected any transactions in the Common Stock since Amendment No. 1 to this Schedule 13D was filed on March 25, 2002.

(d) No person other than the Reporting Persons, Jeffrey M. Elliott and the persons listed on Schedule I has any right to receive or the power to direct the receipt of dividends from, or the proceeds of the sale of any of the Common Stock beneficially owned by the Reporting Persons, except, in the case of the Iridian Reporting Persons, that the dividends from, or proceeds from the sale of, shares of Common Stock in each respective account managed by Iridian (or, in the case of First Eagle, managed by Messrs. Cohen and Levy) will be delivered

Edgar Filing: ICN PHARMACEUTICALS INC - Form SC 13D/A

into each such respective account, and, in the case of FMA, respective advisory clients of FMA.

(e) Not applicable.

SIGNATURES

After reasonable inquiry, and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: April 9, 2002

IRIDIAN ASSET MANAGEMENT LLC

/s/ David L. Cohen

By: David L. Cohen
Title: Principal

LC CAPITAL MANAGEMENT, LLC

/s/ David L. Cohen

By: David L. Cohen
Title: Principal

CL INVESTORS, INC.

/s/ Jeffrey M. Elliott

By: Jeffrey M. Elliott
Title: President

COLE PARTNERS LLC

/s/ David L. Cohen

By: David L. Cohen
Title: Principal

IRIDIAN PRIVATE BUSINESS VALUE
EQUITY FUND, L.P.

By: COLE Partners LLC,
General Partner

/s/ David L. Cohen

By: David L. Cohen
Title: Principal

/s/ David L. Cohen

David L. Cohen, individually

/s/ Harold J. Levy

Harold J. Levy, individually

Edgar Filing: ICN PHARMACEUTICALS INC - Form SC 13D/A

Date: April 9, 2002

FRANKLIN MUTUAL ADVISERS, LLC

/s/ Bradley Takahashi

By: Bradley Takahashi

Title: Assistant Vice President

SCHEDULE IIA

IRIDIAN REPORTING PERSONS
TRANSACTIONS IN COMMON STOCK

Unless otherwise indicated, each of the transactions described below was a purchase of Common Stock for cash on the New York Stock Exchange.

Iridian Asset Management LLC

Date	Number of Shares	Price per Share (1)
March 26, 2002	100	\$32.48

(1) Price excludes commission.

First Eagle Fund of America

March 22, 2002 930 unexercised call options written by First Eagle Fund of America on January 3, 2002, each for 100 shares of Common Stock at a price per share of \$2.20, exercisable at \$35 per share, expired.

SCHEDULE IIB

FMA
TRANSACTIONS IN COMMON STOCK

Unless otherwise indicated, each of the transactions described below

Edgar Filing: ICN PHARMACEUTICALS INC - Form SC 13D/A

was a purchase of Common Stock for cash on the New York Stock Exchange.

Date ----	Number of Shares -----	Price per Share (1) -----
March 25, 2002	107,000	\$31.6848
March 25, 2002	700	\$31.5800
March 26, 2002	230,000	\$32.3128
March 27, 2002	250,000	\$32.3953
March 27, 2002	4,600	\$32.4700
April 3, 2002	103,500	\$30.2556
April 3, 2002	1,500	\$30.2400
April 8, 2002	1,300	\$29.2880
April 9, 2002	262,100	\$30.3650

(1) Price includes commission.